Clinical Trials Logo

Clinical Trial Summary

The rationale for this study is that the risk of anal dysplasia in patients with inflammatory bowel disease (IBD) as compared to the general population has yet to be investigated prospectively. There have only been a few articles examining this relationship - preliminary results have suggested that patients with IBD are at increased risk for abnormal anal pap smears. As high grade anal dysplasia is strongly associated with an increased risk of anal carcinoma, it is important to identify all high risk groups that might benefit from routine screening. This pilot study aims to determine whether patients with IBD in our Bronx population have an increased risk of abnormal anal Pap smears. We hypothesize that there will be an increased incidence of abnormal anal pap smears in patients with IBD who have been treated with immunosuppressants, given that chronic immunosuppression is related to increased HPV infection.


Clinical Trial Description

IBD patients on and off immunosuppression will be identified from gastroenterology fellow clinics. After patients express interest in the study, a study coordinator will provide an overview of the study and obtain consent prior to initiating any research related procedures. Anal Pap smears and Digene Hybrid Capture 2 High-Risk HPV DNA Tests will be performed on each study patient.

Medications will be documented for all IBD subjects and controls. Patient characteristics that will be documented will include IBD diagnosis, area of involvement (small bowel vs. large bowel, rectal involvement), type and duration of immunosuppressant use, smoking status, family history of any dysplasia (including anus), and reproductive risk factors. Data will be reported by subjects in subject interviews and through questionnaires.

For the purposes of analysis, subjects will be divided into two groups: IBD patients on immunosuppression and IBD patients not on immunosuppression. Results will be recorded in relation to exposure to immunosuppressive agents including prednisone, purine analogs (azathioprine/6MP), methotrexate, and infliximab. Immunosuppression will be defined as a history of at least three months of azathioprine/6MP, eight consecutive weeks of prednisone greater than 15mg per day, a cumulative dose of greater than 100mg of methotrexate, or at least one infusion of infliximab within 8 weeks of the date of the anal Pap smear. Since this is a pilot project, we will recruit a minimum of 20 subjects to each group.

Abnormalities will be classified in standard Bethesda classifications as atypical squamous cells of undetermined significance (ASCUS), low grade squamous intraepithelial lesion (LSIL), high grade squamous intraepithelial lesion (HSIL) or carcinoma. The pathologist reading the Pap smears will be blinded to the patient status (IBD versus control) and immunomodulator history. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01653054
Study type Interventional
Source Montefiore Medical Center
Contact
Status Completed
Phase N/A
Start date October 2011
Completion date September 29, 2015

See also
  Status Clinical Trial Phase
Withdrawn NCT04269720 - Biofeedback in Pediatric Inflammatory Bowel Disease N/A
Recruiting NCT04457934 - Effectiveness of PLENVU in the General Screening Population and Patients With IBD
Completed NCT01369355 - A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) Phase 3
Recruiting NCT06146816 - The Assessment of Infrared Treatment for Crohn's Disease N/A
Recruiting NCT05624801 - Cholecalciferol in Chronic Inflammatory Bowel Diseases Phase 3
Recruiting NCT05086562 - Prevalence of Chronic Abdominal Pain in Migraneurs
Recruiting NCT03935451 - Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease Early Phase 1
Recruiting NCT05578768 - Prediction of IBD Disease Activity in Individual Patients Based on PROMs and Clinical Data
Completed NCT04131504 - Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)
Recruiting NCT03952364 - The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States
Enrolling by invitation NCT05414955 - Boom-IBD Clinical Trial N/A
Enrolling by invitation NCT04094324 - Mental Health in Children and Youth Within Pediatric Care
Suspended NCT04225819 - Adjunctive Treatment With Vitamin D3 in Patients With Active IBD N/A
Recruiting NCT03366090 - Immunological Profiles in Inflammatory Bowel Disease N/A
Completed NCT03750565 - Multiple Dose Ethnobridging PK Study in Healthy Subjects Phase 1
Recruiting NCT02970149 - Identifying a Sleep Screener for Disease Relapse in Children With Inflammatory Bowel Disease N/A
Completed NCT02622139 - Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Diseases (IBD) N/A
Completed NCT02364973 - Combined PET-MRI in the Diagnostics of Chronic Inflammatory Bowel Diseases (IBD)- a Feasibility Study
Not yet recruiting NCT06090045 - Airway Involvement In Inflammatory Bowel Disease
Not yet recruiting NCT06089590 - Ibd CAncer and seRious Infections in France (I-CARE 2)